Búsqueda | Portal de Búsqueda de la BVS España

1.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins, D; Orkin, C; Daar, E S; Mills, A; Brinson, C; DeJesus, E; Post, F A; Morales-Ramirez, J; Thompson, M; Osiyemi, O; Rashbaum, B; Stellbrink, H-J; Martorell, C; Liu, H; Liu, Y-P; Porter, D; Collins, S E; SenGupta, D; Das, M.

HIV Med; 19(10): 724-733, 2018 11.

Artículo en Inglés | MEDLINE | ID: mdl-30101539

2.

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

Wohl, D A; Bhatti, L; Small, C B; Edelstein, H; Zhao, H H; Margolis, D A; DeJesus, E; Weinberg, W G; Ross, L L; Shaefer, M S.

HIV Med; 17(2): 106-17, 2016 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-26176344

3.

A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding.

DeJesus, E; Kieft, R; Albright, B; Stephens, N A; Hajduk, S L.

PLoS Pathog; 9(4): e1003317, 2013.

Artículo en Inglés | MEDLINE | ID: mdl-23637606

4.

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Campo, R; DeJesus, E; Bredeek, U F; Henry, K; Khanlou, H; Logue, K; Brinson, C; Benson, P; Dau, L; Wang, H; White, K; Flaherty, J; Fralich, T; Guyer, B; Piontkowsky, D.

Clin Infect Dis; 56(11): 1637-45, 2013 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-23362296

5.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin, C; DeJesus, E; Khanlou, H; Stoehr, A; Supparatpinyo, K; Lathouwers, E; Lefebvre, E; Opsomer, M; Van de Casteele, T; Tomaka, F.

HIV Med; 14(1): 49-59, 2013 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-23088336

6.

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

Vrouenraets, S M E; Wit, F W N M; Fernandez Garcia, E; Moyle, G J; Jackson, A G; Allavena, C; Raffi, F; Jayaweera, D T; Mauss, S; Katlama, C; Fisher, M; Slama, L; Hardy, W D; Dejesus, E; van Eeden, A; Reiss, P.

HIV Med; 12(10): 620-31, 2011 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-21819530

7.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Dejesus, E; Mills, A; Bhatti, L; Conner, C; Storfer, S.

Int J Clin Pract; 65(12): 1240-9, 2011 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-21999631

8.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross, L L; Rouse, E; Gerondelis, P; DeJesus, E; Cohen, C; Horton, J; Ha, B; Lanier, E R; Elion, R.

J Antimicrob Chemother; 65(2): 307-15, 2010 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-20008905

9.

Repression of rearranged mu gene and translocated c-myc in mouse 3T3 cells X Burkitt lymphoma cell hybrids.

Nishikura, K; ar-Rushdi, A; Erikson, J; DeJesus, E; Dugan, D; Croce, C M.

Science; 224(4647): 399-402, 1984 Apr 27.

Artículo en Inglés | MEDLINE | ID: mdl-6424234

10.

96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial.

Young, B; Vanig, T; DeJesus, E; Hawkins, T; St Clair, M; Stancil, B; Ha, B.

HIV Clin Trials; 12(4): 228-33, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-22044859

11.

Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes.

Nesbit, M; Nesbit, H K; Bennett, J; Andl, T; Hsu, M Y; Dejesus, E; McBrian, M; Gupta, A R; Eck, S L; Herlyn, M.

Oncogene; 18(47): 6469-76, 1999 Nov 11.

Artículo en Inglés | MEDLINE | ID: mdl-10597249

12.

Portrait of a pusher--"mother".

Tozman, S; DeJesus, E.

J Clin Psychiatry; 39(8): 656-9, 1978 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-681302

13.

Melanoma cell lines from different stages of progression and their biological and molecular analyses.

Satyamoorthy, K; DeJesus, E; Linnenbach, A J; Kraj, B; Kornreich, D L; Rendle, S; Elder, D E; Herlyn, M.

Melanoma Res; 7 Suppl 2: S35-42, 1997 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9578415

14.

Developmental issues in deaf children.

Schilling, L S; DeJesus, E.

J Pediatr Health Care; 7(4): 161-6, 1993.

Artículo en Inglés | MEDLINE | ID: mdl-8350237

15.

Claims processing speeds up.

DeJesus, E X.

Healthc Inform; 17(6): 45-6, 48-50, 52, 2000 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-11067202

16.

Managing managed care.

DeJesus, E X.

Healthc Inform; 16(3): 31-40, 1999 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-10350786

17.

Date with destiny.

DeJesus, E X.

Healthc Inform; 16(1): 49-50, 52, 54-6, 1999 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-10345766

18.

Integrating PACS power.

DeJesus, E X.

Healthc Inform; 15(11): 97-100, 102-3, 1998 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-10185708

19.

An inch of performance is worth a mile of cure.

DeJesus, E X.

Mater Manag Health Care; 10(9): 18-21, 2001 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-11573302

20.

Waste not, want not.

DeJesus, E X.

Mater Manag Health Care; 10(8): 16-9, 2001 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-11530538

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding.

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Repression of rearranged mu gene and translocated c-myc in mouse 3T3 cells X Burkitt lymphoma cell hybrids.

96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial.

Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes.

Portrait of a pusher--"mother".

Melanoma cell lines from different stages of progression and their biological and molecular analyses.

Developmental issues in deaf children.

Claims processing speeds up.

Managing managed care.

Date with destiny.

Integrating PACS power.

An inch of performance is worth a mile of cure.

Waste not, want not.